IMMUNOCORE HLDGS ADS/1 (6YG) — Cash Flow-to-Debt Ratio
IMMUNOCORE HLDGS ADS/1 (6YG) has a Cash Flow-to-Debt Ratio of -0.05x as of December 2025, meaning its operating cash flow of €-32.66 Million could theoretically repay 0% of its total liabilities (€686.24 Million) in one year. See how much free cash does IMMUNOCORE HLDGS ADS/1 generate to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
IMMUNOCORE HLDGS ADS/1 Cash Flow-to-Debt Ratio (2022–2025)
Historical debt coverage capacity for IMMUNOCORE HLDGS ADS/1 across 4 annual periods. Also explore IMMUNOCORE HLDGS ADS/1 annual equity growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for IMMUNOCORE HLDGS ADS/1 (2022–2025)
Year-by-year debt coverage analysis for IMMUNOCORE HLDGS ADS/1. For market capitalisation and broader financial context, see IMMUNOCORE HLDGS ADS/1 (6YG) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.02x | €-10.71 Million | €686.24 Million | ▼ -138.9% |
| 2024 | 0.04x | €26.06 Million | €648.79 Million | ▲ +211.7% |
| 2023 | 0.01x | €2.94 Million | €228.16 Million | ▲ +104.9% |
| 2022 | -0.26x | €-49.21 Million | €187.86 Million | — |